Starr collaboration illuminates mysterious pathway to immortality in cancer cells

July 25, 2012 By Joseph Bonner
Cell lines lacking ALT (top row) showed a nearly complete disappearance of the irradiation-induced DNA damage after 24 hours (far right column). In contrast, 11 out of 12 ALT cell lines (bottom row) retained a significant fraction of the induced DNA damage foci after a day. Cells in the left hand column were not irradiated; the center column shows DNA damage one hour after irradiation.

(Medical Xpress) -- Cancer cells are immortal because they circumvent failsafe mechanisms that stop out-of-control cell proliferation. One of these mechanisms – the progressive shortening of chromosomes – is prevented by replenishment of telomeres, the protective elements at the ends of chromosomes. Most cancer cells do this with an enzyme called telomerase, but approximately 10 to 15 percent of human cancers use a different pathway called ALT (alternative lengthening of telomeres). Whether or not a tumor has ALT makes a difference. For example, people with glioblastoma live twice as long if the tumor uses ALT.

With support from the Starr Cancer Consortium, a team of scientists from The Rockefeller University, The Broad Institute of MIT and Harvard, Memorial Sloan-Kettering Center and Weill Cornell Medical College set out to demystify ALT. The team carried out a detailed analysis of a large panel of ALT cell lines for their genetic and cell biological features. How ALT is activated was not known but recent data pointed the finger at an enzyme called ATRX. ATRX changes the way DNA wraps around proteins in chromosomes.

In an article published online July 19 in PLoS Genetics the team shows that loss of ATRX is a common event in the genesis of ALT lines. They also show that ALT cell lines frequently undergo chromosomal changes and are impaired in their ability to detect and repair damage in their DNA.

“These hallmarks of ALT are expected to help the detection of ALT-type tumors in the clinic and may lead to ALT-specific treatments,” says Titia de Lange, Leon Hess Professor and head of the Laboratory of Cell Biology and Genetics at Rockefeller University, team leader and co-author of the paper. They may also help explain differential survival benefit of ALT tumors.”

“This work represents a remarkable collaborative effort among five laboratories at four different institutions,” says John Petrini, a member of Memorial Sloan-Kettering’s Molecular Biology Program, team member and co-author of the paper. “Each of us brought our specific expertise to bear on this intriguing and important problem.”

“It exemplifies the power of collaboration,” says William Hahn, a senior associate member of the Broad Institute, team member and co-author of the paper.

Explore further: Alternate ending -- living on without telomerase

More information: www.starrcancer.org/

Related Stories

Alternate ending -- living on without telomerase

November 3, 2011
Scientists of the German Cancer Research Center have discovered an alternative mechanism for the extension of the telomere repeat sequence by DNA repair enzymes.

Researchers report new understanding of role of telomeres in tumor growth

September 1, 2011
The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal ...

Genetic controller prepares immune system for diverse threats

September 11, 2011
An army of immune cells circulates the human body to protect against its potential foes—viruses, bacteria, cancer cells, and other invaders. Because the immune system cannot know what to expect, it must be prepared to ...

Blocking telomerase kills cancer cells but provokes resistance, progression

February 21, 2012
Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.